In line with these findings, several clinical trials aiming to analyzing the combination of palbociclib in combination with carboplatin or PI3K/mTOR inhibitors in advanced, recurrent or unresectable cases of HNSCC and other solid tumors are in progress (clinicaltrials.gov: NCT03194373, NCT03065062). Here, MTOR is linked to head and neck squamous cell carcinoma.